These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34477047)

  • 1. RecQ-like helicase 4 (RECQL4) exacerbates resistance to oxaliplatin in colon adenocarcinoma via activation of the PI3K/AKT signaling pathway.
    Zhou F; Wang L; Jin K; Wu Y
    Bioengineered; 2021 Dec; 12(1):5859-5869. PubMed ID: 34477047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K/AKT/mTOR.
    Ren J; Hu Z; Niu G; Xia J; Wang X; Hong R; Gu J; Wang D; Ke C
    FASEB J; 2023 Mar; 37(3):e22790. PubMed ID: 36786694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-708 targeting ZNF549 regulates colon adenocarcinoma development through PI3K/AKt pathway.
    Zhao Z; Qin X
    Sci Rep; 2020 Oct; 10(1):16729. PubMed ID: 33028966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
    Liu Y; Bi T; Wang Z; Wu G; Qian L; Gao Q; Shen G
    Apoptosis; 2016 Dec; 21(12):1398-1407. PubMed ID: 27671687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway.
    Mo D; Fang H; Niu K; Liu J; Wu M; Li S; Zhu T; Aleskandarany MA; Arora A; Lobo DN; Madhusudan S; Balajee AS; Chi Z; Zhao Y
    Cancer Res; 2016 May; 76(10):3057-66. PubMed ID: 27013200
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ma L; Ai F; Xiao H; Wang F; Shi L; Bai X; Zhu Y; Ma W
    Front Pharmacol; 2024; 15():1367747. PubMed ID: 38576495
    [No Abstract]   [Full Text] [Related]  

  • 7. ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance.
    Lin L; Li X; Pan C; Lin W; Shao R; Liu Y; Zhang J; Luo Y; Qian K; Shi M; Bin J; Liao Y; Liao W
    Cell Death Dis; 2019 Feb; 10(3):173. PubMed ID: 30787271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZNF692 promotes colon adenocarcinoma cell growth and metastasis by activating the PI3K/AKT pathway.
    Xing Y; Ren S; Ai L; Sun W; Zhao Z; Jiang F; Zhu Y; Piao D
    Int J Oncol; 2019 May; 54(5):1691-1703. PubMed ID: 30816443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystatin SA attenuates gastric cancer cells growth and increases sensitivity to oxaliplatin via PI3K/AKT signaling pathway.
    Lu Y; Wang H; Chen S; Yang B; Li Y; Li Y
    J Cancer Res Clin Oncol; 2024 May; 150(5):244. PubMed ID: 38717526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
    Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
    Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway.
    Sui H; Pan SF; Feng Y; Jin BH; Liu X; Zhou LH; Hou FG; Wang WH; Fu XL; Han ZF; Ren JL; Shi XL; Zhu HR; Li Q
    BMC Complement Altern Med; 2014 Aug; 14():279. PubMed ID: 25085593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.
    Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X
    Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAF5 promotes the occurrence and development of colon cancer via the activation of PI3K/AKT/NF-κB signaling pathways.
    Sun G; Zheng C; Deng Z; Huang C; Huang J
    J Biol Regul Homeost Agents; 2020; 34(4):1257-1268. PubMed ID: 32911926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
    Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.
    Zhang Y; Liu X; Zhang J; Xu Y; Shao J; Hu Y; Shu P; Cheng H
    Aging (Albany NY); 2020 Mar; 12(7):5640-5650. PubMed ID: 32209726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL3-CCR5 axis promotes cell migration and invasion of colon adenocarcinoma via Akt signaling pathway.
    Guan B; Li H; Yao J; Guo J; Yu F; Li G; Wan B; Ma J; Huang D; Sun L; Chen Y
    Environ Toxicol; 2023 Jan; 38(1):172-184. PubMed ID: 36346222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. lncRNA EZR‑AS1 knockdown represses proliferation, migration and invasion of cSCC via the PI3K/AKT signaling pathway.
    Lu D; Sun L; Li Z; Mu Z
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.